Synairgen (SNG)

 

SNG Share PerformanceMore

52 week high32.00 22/03/17
52 week low6.98 05/09/17
52 week change -0.63 (-4.63%)
4 week volume15,073,873 21/11/17

Media for (SNG)

Presenter: Richard Marsden, CEO
11/11/2014
Presenter: Richard Marsden
07/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Synairgen revises collaboration with Pharmaxis

Synairgen, the respiratory drug discovery and development company, has revised its collaboration agreement with Pharm...

Update on LOXL2 Programme&Pharmaxis Collaboration

RNS Number: 3339Z Synairgen plc 14 December 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Update on LOXL2 Programme and Collaboration with Pharmaxis 5M payment to Synairgen plus percentage of all future partnering revenues Southampton, UK - 14 December 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development co...

Holding(s) in Company

RNS Number: 9658V Synairgen plc 08 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Synairgen Plc 1b. Ple...

Data update and clinical plan for COPD

RNS Number: 8968R Synairgen plc 27 September 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Data update from clinical trial of inhaled interferon beta (SNG001) and clinical plan for COPD - Significant positive findings in patients with a confirmed viral infection in the INEXAS trial - COPD Phase II clinical trial designed Southampton, UK - 27 Sep...

Interim results for six months ended 30 June 2017

RNS Number: 8967R Synairgen plc 27 September 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2017 Southampton, UK - 27 September 2017: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces its unaudited interim results for the six months ended 30 J...

Holding(s) in Company

RNS Number: 6531Q Synairgen plc 13 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Synairgen Plc 1b. Pleas...

Synairgen's PXS-5382A to be prepared for Phase I clinical development

Synairgen announced following the successful completion of preclinical pharmacology and toxicology studies, a compound...

LOXL2 Inhibitor Update.

RNS Number: 9400P Synairgen plc 06 September 2017 Press release Synairgen plc ('Synairgen' or the 'Company') LOXL2 Inhibitor Update - Successful completion of LOXL2 preclinical studies - Phase I trial on track to commence in Q4 2017 Southampton, UK - 6 September 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development company, is please...

Fundamental DataMore

EPS-3.08
Dividend yield0 %

Latest discussion posts More

  • some good news

    a decent per cent of any future revenues without any more cash commitment thru remaining testing etc.. 5m Cash in the bank is very useful too.. I added some this morning and ...
    14-Dec-2017
    Nice to Michu
  • Re: Rns's

    No problem, but it does seem that things have turned poitive again. Potential is huge if all goes well.
    27-Oct-2017
    Bitethebull
  • Re: Rns's

    My error - I saw 27th and thought that it was today...not last month. Been in this for ages so no a downhill ride, and I don't check the BB very often - not until this ...
    27-Oct-2017
    charlie51

Users' HoldingsMore

Users who hold Synairgen also hold..

Codes & Symbols

ISINGB00B0381Z20
SymbolsSNG, LSE:SNG, SNG.L, SNG:LN, LON:SNG, XLON:SNG

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account